scispace - formally typeset
Journal ArticleDOI

Anti-cancer drugs

Elke S. Bergmann-Leitner
- 31 Mar 2005 - 
- Vol. 14, Iss: 11, pp 1048-1048
Reads0
Chats0
About
This article is published in Current Pharmaceutical Design.The article was published on 2005-03-31. It has received 882 citations till now. The article focuses on the topics: Introductory Journal Article.

read more

Citations
More filters
Journal ArticleDOI

Coencapsulation of Arsenic‐ and Platinum‐based Drugs for Targeted Cancer Treatment

TL;DR: Lipid-based carriers have been successfully applied in clinics for improving the therapeutic efficacy of numerous drugs, such as liposomal doxorubicin (Doxil®), mainly via the enhanced permeability and retention (EPR) effects.
Journal ArticleDOI

Antitumor activities of ferrocene compounds

TL;DR: In this paper, data on the antitumor activities of ferrocene compounds and the results concerning the mechanisms of their action published between 1995 and 2010 are discussed and the biomedical aspects of the study of Ferrocene derivatives are briefly analyzed.
Journal ArticleDOI

Involvement of PKC and ROS in the cytotoxic mechanism of anti-leukemic decursin and its derivatives and their structure-activity relationship in human K562 erythroleukemia and U937 myeloleukemia cells.

TL;DR: The structure-activity relationship of decursin and its derivatives is as follows: the coumarin structure is required for anti-leukemic activity and the side chain is a determinant of PKC activation and the cytotoxic mechanism in leukemia cells.
Journal ArticleDOI

Ferrocenes as potential anticancer drugs. Facts and hypotheses

TL;DR: In this paper, the authors analyzed the research data on antitumor effects of a wide range of ferrocene compounds and discussed possible mechanisms of their bioactivities, and proposed promising ways in the design of low-toxicity anticancer Ferrocene-based drugs of new generation.
Journal ArticleDOI

The role of doxorubicin and epirubicin in the treatment of patients with metastatic hormone-refractory prostate cancer

TL;DR: The majority of reviewed studies reported a pain reduction in >50% of patients receiving Dox or Epi, suggesting a substantial palliative effect by their use in metastatic HRPC, suggesting the combination of docetaxel with active agents such as anthracyclines may deserve further clinical investigation.
References
More filters
Journal ArticleDOI

The status of platinum anticancer drugs in the clinic and in clinical trials.

TL;DR: The status of platinum anticancer drugs currently approved for use, those undergoing clinical trials and those discontinued during clinical trials are updated, and the results in the context of where the field will develop over the next decade are discussed.
Journal ArticleDOI

Natural products to drugs: natural product derived compounds in clinical trials

TL;DR: Natural product and natural product-derived compounds that are being evaluated in clinical trials or are in registration (as at 31st December 2007) have been reviewed, as well as natural products for which clinical trials have been halted or discontinued since 2005.
Journal ArticleDOI

Cellular distribution and functions of P2 receptor subtypes in different systems.

TL;DR: This review is aimed at providing readers with a comprehensive reference article about the distribution and function of P2 receptors in all the organs, tissues, and cells in the body.
Journal ArticleDOI

Natural products: an evolving role in future drug discovery.

TL;DR: The present review describes natural products, semi-synthetic NPs and NP-derived compounds that have undergone clinical evaluation or registration from 2005 to 2010 by disease area i.e. infectious, immunological, cardiovascular, neurological, inflammatory and related diseases and oncology.